$ANAB

Global markets are mixed as crude oil prices and bond yields rise. Saudi Arabia aims to restore half of its East-West pipeline capacity, which was shut due to drone strikes. Markets price in a 58% chance of a 25 bp Fed rate hike. Software and cybersecurity stocks fall, while chipmakers and crypto-exposed stocks rise. Netflix drops after a downgrade, and Nucor declines on weaker earnings guidance. Bitcoin gains over 2% after SEC's digital securities plan.

AnaptysBio Inc. is set to report Q2 earnings, with investors watching if Jemperli royalty growth can offset a 21% revenue decline. Analysts expect a loss of $0.13 per share on $20.2M revenue. All 11 analysts rate it a Strong Buy, with a mean target of $86.64. Jemperli's FDA priority review for rectal cancer and imsidolimab's regulatory decision in December are key catalysts. The company has a $100M buyback plan and a market cap of $1.67B.

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 11, 2026, AnaptysBio, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of two Class III directors, Hollings Renton and John P. Schmid,

Laughing Water Capital’s Q2 2026 investor letter said its Class A portfolio returned about 39.8% net of fees in Q2 and 33.6% YTD. The letter highlighted AnaptysBio (NASDAQ:ANAB) as a newly added position after a taxable spinoff. It cited ANAB’s July 13 close at $69.81 and described a July 14-17 trial involving GSK over Jemperli royalties.

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001370053 false 0001370053 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15,

ANAPTYSBIO, INC (ANAB) filed a Rule 144 notice regarding the proposed sale of 15,467 shares of common stock stemming from a stock option exercise dated May 21, 2026. The filing also disclosed two previous dispositions by Dennis Mulroy totaling 20,000 shares in mid-May 2026. This is a routine compliance filing, categorized as neutral in its impact and sentiment.

AnaptysBio, Inc. has successfully spun off its biopharma operations into First Tracks Biotherapeutics, Inc., transforming itself into a royalty management entity. The company will now focus on financial collaborations for Jemperli and imsidolimab, operating virtually with minimal expenses and a strong cash position. This restructuring has led to a significant return for ANAB shareholders, with First Tracks Bio independently trading under the symbol TRAX on Nasdaq.

Skandinaviska Enskilda Banken AB publ significantly increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 333.1% in Q3, now holding 145,191 shares valued at approximately $4.45 million. Other institutional investors like Assenagon Asset Management S.A. also dramatically boosted their holdings, indicating strong institutional accumulation. AnaptysBio's board has authorized a $100 million share buyback, and analysts maintain a "Moderate Buy" rating with an average target price of $66.89 against a current trading price near $54.

AnaptysBio (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of the company's stock for $540,000 on February 11th, reducing his ownership by 43.79%. Following this transaction, Loumeau now owns 12,835 shares valued at approximately $693,090. The biotechnology company also recently announced a $100 million stock repurchase plan, indicating management believes the stock is undervalued.

ANAPTYSBIO INC (NASDAQ:ANAB) aligns with Mark Minervini's investment strategy, showing strong technical health and fundamental improvement. The stock meets the Minervini Trend Template criteria, indicating a clear upward trend and outperforms the broader market, with a ChartMill Relative Strength score of 97.29. Fundamentally, ANAB demonstrates high growth momentum through significant year-over-year EPS and revenue increases, alongside a recent shift to profitability, making it a compelling candidate for high-growth momentum investors.